TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subject has received mechanical ventilation for at least 48h at the time of the randomisation~* Acute Physiology and Chronic Health Evaluation (APACHE) of 8 to 30, inclusive, within 24h prior to randomization~* Presence of new or progressive infiltrate on chest X-ray~* Presence of clinical criteria consistent with VABP~* High probability of VABP caused by Pseudomonas aeriginosa~Key Exclusion Criteria:~* Known or suspected community-acquired bacterial pneumonia or viral, fungal, or parasitic pneumonia~* Known hypersensitivity or contra-indications to beta-lactam antibiotics, aminoglycosides, quinolones, colistin, or subjects with a clinically significant history of anaphylactic reaction~* Severe liver or renal impairment~* Women who are pregnant or nursing, or who are of chilbearing potential and unwilling to use acceptable method of birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Murepavadin (Type: EXPERIMENTAL): Murepavadin IV + one anti-pseudomonal antibiotic
- Two anti-pseudomonal antibiotics (Type: ACTIVE_COMPARATOR): Association of 2 anti-pseudomonal antibiotics

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \>35 week Gestational Age (GA) at birth~* \<3 months (90 days) old chronological age at the time of enrollment~* Exposed to a minimum five days of continuous narcotic infusion~Exclusion Criteria:~* Neurologic abnormality which would make Neonatal Abstinence Score (NAS) scoring inaccurate~* Major chromosomal abnormality (with the exception of Trisomy 21)~* Infant already enrolled in another randomized, controlled clinical trial

- Gender: ALL
- Minimum Age: 5 Days
- Maximum Age: 90 Days
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Interventions: Infants will receive intravenous or oral clonidine(Duraclon) for the treatment of pain and sedation: Duration: (Clonidine HCL) 1 mcg/kg/dose q4 either iv or po.
- Control (Type: PLACEBO_COMPARATOR): Intervention: Infants will receive place (saline) (if receiving it IV) or orally (sterile water) if receiving it orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Velcade and Thalidomide in Patients With Myelodysplasia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Myelodysplastic syndrome with a IPSS score of 0.5 or greater~* May have had prior chemo/radiotherapy for another malignancy or myelodysplasia~* ECOG performance status of 0-2~* Life expectancy greater than 3 months~* Total bilirubin \</+ 2xULN~* ALT and AST \</+ 3xULN~* Calculated creatinine clearance \> 30 ml/min~* Use of appropriate method of contraception during the study~* ANC \> 0.5 x 10(9)~* Platelet count \> 30 x 10(9)~* Consideration of treatment with 5 azacytidine is encouraged by not required~Exclusion Criteria:~* Ejection fraction \< 40%~* myocardial infarction within 6 months of enrollment of New York Heart Association Class III or IV heart failure, uncontrolled angina, uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities~* Women who are pregnant or breast-feeding~* Major surgery within 4 weeks prior to enrollment~* \>/= grade 2 peripheral neuropathy within 14 days prior to enrollment~* Uncontrolled intercurrent illness~* Serious medical or psychiatric illness that could potentially interfere with the completion of treatment~* Hypersensitivity to bortezomib, boron, or mannitol~* Received an investigational drug within 14 days of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Low Dose Ketamine Infusion

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients will be eligible if they meet the following criteria:~* Children age one three (3) years to eighteen (18) years, requiring admission to the Pediatric ICU, who require intubation for respiratory failure and continuous infusion fentanyl.~* Patients of both genders, all races and ethnic backgrounds will be eligible.~* Patients will need to have AST and ALT evaluated within the two weeks prior to enrollment, with the result being within two times the normal range. Patients who have not had AST and ALT evaluated within two weeks will have to be evaluated prior to enrollment. Serum will be evaluated for AST and ALT when convenient to other lab testing prior to enrollment.~* Patients meeting the above criteria will be eligible regardless of nutritional status, performance status or recovery from prior medical treatment.~* Patients will not be excluded if they require simultaneous infusions of sedation with benzodiazepine.~* Enrollment will require parental consent.~Exclusion Criteria:~* Patients will not be eligible if they meet any of the following criteria:~* Patients who are currently on oral analgesia or sedation~* Patients who have a prior history of drug or alcohol dependence/abuse.~* Patients who are allergic to opioids.~* Patients who are allergic to ketamine or any NMDA antagonist. Patients in whom significant elevation of blood pressure would constitute a serious hazard~* Patients with documented or clinical concern for elevated intracranial pressure.~* Patients with known liver dysfunction as evidenced by AST and ALT two times the normal limit within the past two weeks.~* Patients who are being medically paralyzed as part of their current treatment.~* Patients with any underlying neurologic condition, or impairment, which would interfere with their perception of, or response to, pain or discomfort.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Ketamine will be administered in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr to in PICU patients that meet eligibility criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Immediate Parent -Infant Skin-to-Skin Study (IPISTOSS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Born in gestation week plus days 28+0 - 32+6.~* Born at maternity ward at study center~* Consent from parents/caregivers~* Parent or caregiver or substitute are available to start skin-to-skin Contact during the first hour of life.~Exclusion Criteria:~* Born outside the hospital~* Triplets or more~* Known malformation which will require immediate surgical action~* On-going resuscitation or intensive Medical care (mechanic ventilation or inotropy) after the first lifespan~  \* Known congenital infection~* Parent/care giver can not communicate in Swedish/Norwegian or English~* Not suited for the study for other reasons (according to the principal investigator)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Skin-to-skin Contact group (Type: EXPERIMENTAL): Neonates in gestational age between 28+0 - 32+6 will get continuous Skin-to-skin contact with one parent/caregiver the first 6 hours after birth and as much as possible the first 72 hours after birth.
- Conventional care group (Type: ACTIVE_COMPARATOR): Neonates in gestational age between 28+0 - 32+6 will get Conventional care - incubators, warmers etc - the first 72 hours after birth.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Gladiator Cemented Femoral Stems

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Has undergone primary THA for any of the following:~* Non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, or painful hip dysplasia;~* Inflammatory degenerative joint disease such as rheumatoid arthritis; or~* Correction of functional deformity~* Subject is implanted with the specified combination of components~* Subject is willing and able to complete required study visits or assessments~Exclusion Criteria:~* Subjects implanted with a metal-on-metal articulation~* Subjects implanted with non-MPO or non-Wright Medical Technology components (femoral heads, acetabular shells, acetabular liners) in the enrolled THA~* Subjects skeletally immature (less than 21 years of age) at time of primary THA surgery~* Subjects currently enrolled in another clinical study which could affect the endpoints of this protocol~* Subjects unwilling to sign the Informed Consent document~* Subjects with substance abuse issues~* Subjects who are incarcerated or have pending incarceration

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Total Hip Arthroplasty (Type: None): Single group previously implanted with the following combination of components: PROFEMUR® Gladiator femoral stem, MicroPort acetabular shell, MicroPort Orthopedics polyethylene or ceramic liner, MicroPort Orthopedics metal or ceramic femoral head.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Motorized Continuous Cold Therapy Versus Standard Post-op Icing Protocol for Two Foot and Ankle Procedures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are scheduled to have either lateral ankle ligament reconstruction (LAR) surgery or primary first metatarsal osteotomy surgery~* Patients who agree to be compliant and to keep a patient diary daily for 2 weeks and to return to the clinic for a 2 week postoperative follow- up appointment~Exclusion Criteria:~* Patients with Diabetes Mellitus, peripheral vascular disease, Reynauds Syndrome, hypersensitivity to cold~* Patients allergic to hydrocodone or oxycodone~* Patients who are unwilling to complete the patient diary and/or follow their specific cold therapy instructions

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Foot and Ankle Surgery (Type: OTHER): Please note that the study was terminated prior to randomization of patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients With Non-Hodgkin's Lymphoma(NHL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Capable of giving written informed consent, and willing and able to comply with the requirements and restrictions listed in the consent form.~2. Male or female patients \>18 years of age at screening with histological or cytological diagnosis of Non-Hodgkin's Lymphoma and due to receive intravenous chemotherapy for the first time~3. A female subject is eligible to participate if she has non-childbearing potential~4. Male subject must agree to use one of the contraception methods listed~5. Able to lie comfortably on back for up to 70 minutes at a time.~6. WHO performance status 0, 1 or 2 -~Exclusion Criteria:~1. Patients with known history of Hepatitis B, C, non-A, non-B and HIV~2. Any clinically significant medical conditions that in the opinion of the investigator would compromise the compliance with study procedures.~3. Pregnant or breast feeding females.~4. Any other prior anticancer therapy~5. Any new investigational agent, including an investigational anti-cancer agent~6. History of sensitivity to heparin or heparin-induced thrombocytopenia.~7. Males and females not able to comply with contraceptive guidelines during the study.~   -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- no treatment (Type: NO_INTERVENTION): no treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Suprathel Versus Xeroform for the Management of Skin Graft Donor Sites

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children 31 days old -17 years old~* Have a burn injury or open wound of any percentage TBSA~* Require a skin graft~Exclusion Criteria:~* allergy to one of the dressings involved in the study,~* burn in close proximity to the donor site,~* the donor site has been harvested in a previous surgery,~* prisoners,~* children under the protection of the department of human services,~* pregnant women,~* those with impaired decision-making capacity.

- Gender: ALL
- Minimum Age: 31 Days
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Suprathel (Type: EXPERIMENTAL): Once hemostasis is obtained, the Suprathel material will be handled with a new pair of sterile gloves. It will be cut so that the material extends 1-2 cm beyond the donor site margins, then applied to the donor site. The Suprathel will be secured with a protective layer of Rylon extending 1-2 cms beyond the margins of the Suprathel. The primary dressing will be covered with cotton gauze (4x4 fluff gauze pads) and wrapped with rolled gauze). The outer dressing will be changed 7-10 days post-op. The Suprathel and Rylon will remain in place until they can be easily peeled off. To facilitate the pain-free and easy removal of the primary Suprathel dressing, practioners will apply Vaseline or lotion to saturate and loosen the material. The patients will be followed on average about once per week in an outpatient clinic until the Suprathel (and Rylon) are removed, but they may continue to be seen until the STSG is fully healed.
- Xeroform (Type: ACTIVE_COMPARATOR): After hemostasis occurs, the Xeroform dressing will be handled with a new pair of sterile gloves and cut so that the material extends 1-2 cm beyond the donor site margins, then applied to the donor site. The primary dressing will be covered with cotton gauze (4x4 fluff gauze pads) and wrapped with rolled gauze (Kerlix). The outer dressing will be changed 7-10 days post-op. The Xeroform will remain in place until it can be easily peeled off. To facilitate the pain-free and easy removal of the Xeroform dressing, practioners may apply Vaseline or lotion to saturate and loosen the material. The patients will be followed on average about once per week in an outpatient clinic until the Xeroform is removed, but they may continue to be seen until the STSG is fully healed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Daily Co-trimoxazole Prophylaxis to Prevent Malaria in Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed pregnancy (through palpable fundus and/ or positive pregnancy test)~* Gestational age between 16 and 28 weeks.~* Informed consent by patient (or parent/ guardian if patient is less than 18 years of age)~* No symptoms consistent with malaria~* Willingness to deliver at the health facility~* Willingness to adhere to all requirements of the study (including HIV-1 testing)~Exclusion Criteria:~* History of allergy to study drugs, or previous history of allergy to sulpha drugs~* History or presence of major illnesses likely to influence pregnancy outcome including diabetes mellitus, severe renal or heart disease, or active tuberculosis, prior to randomization;~* Any significant illness that requires hospitalization;~* Intent to move out of the study catchment's area before delivery or deliver at relative's home out of the catchment's area;~* Prior enrolment in the study or concurrent enrolment in another study~* Severe anaemia (Hb\<7 g/dl)~* Previous history of unfavourable pregnancy outcome: pre-eclampsia, caesarean section, stillbirth.~* Being HIV infected and already receiving CTX prophylaxis or ARV treatment

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): HIV-negative women taking CTX as chemoprophylaxis
- 2 (Type: ACTIVE_COMPARATOR): HIV-negative women taking SP as IPT
- 3 (Type: EXPERIMENTAL): HIV-positive women (CD4\> 200) taking CTX as chemoprophylaxis
- 4 (Type: ACTIVE_COMPARATOR): HIV-positive women (CD4 \> 200) taking SP as IPT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 40 and 89 years old~* Diagnosis of treated POAG (including normal tension glaucoma (NTG))~* All IOP measurements during the VF period (to be described further) equal or lower than 18 mmHg and/or on average equal or lower than 16 mmHg in the same period~* Documented glaucomatous VF damage at baseline, characterized by glaucoma hemifield test result outside normal limits on at least 2 consecutive VF tests or the presence of at least 3 contiguous test points within the same hemifield on the pattern deviation plot at p\<0.01, with at least 1 point at p \< 0.005~* At least 8 visual field tests carried out within at least 2 years, all with fixation losses and false positive/negative results equal or less than 33%~* For fast progressing eyes, 1) pointwise progression defined as two or more adjacent VF test locations in the same hemifield that show a threshold sensitivity rate of change more negative than -1.0 dB/year with p\<0.01 or 2) a global rate of VF change based on mean deviation (MD) more negative than -1.0 dB/year~* For slowly or minimally progressing eyes a VF MD rate of change more positive than -0.5 dB/year with no significant pointwise progression as described above~* Not more than 6 diopters spherical equivalent on the study eye~* Have given written informed consent, prior to any investigational procedures~Exclusion Criteria:~* Baseline VF MD more negative than -15 dB. The rationale here is that in severely damaged visual fields, one may not be able to detect and measure rates of progression due to a 'floor effect'~* Corneal or conjunctival abnormality precluding contact lens adaptation~* Severe dry eye syndrome or other ocular disease~* Patients with angle closure glaucoma, traumatic glaucoma or uveitic glaucoma~* Patients with previous intraocular surgery in the enrolled eye, including cataract surgery~* Patients with allergy to corneal anesthetic~* Patients with contraindications for silicone contact lens wear~* Patients not able to understand the character and individual consequences of the investigation~* Participation in unrelated clinical research within the last 4 weeks

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- SENSIMED Triggerfish® (Type: EXPERIMENTAL): Device: portable device that monitors the 24-hour IOP pattern by a wireless contact lens sensor placed on the eye that sends its signals via an antenna around the orbital cavity to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues